Impact
Impact
Thanks to Gavi’s work in the past two decades, child mortality is at its lowest, and today’s generation is set to be the healthiest yet. When Gavi, the Vaccine Alliance was established in 2000, almost ten million children globally would die annually before their fifth birthday. By 2017, this number had almost halved. Since its inception, Gavi has protected a whole generation of children, 822 million of them, and saved over 14 million lives from potentially fatal infectious diseases.
IFFIm has played a role in speeding delivery of funding. To date, IFFIm has provided over 19% of Gavi’s programme funding, disbursing approximately US$ 3.1 billion to support Gavi’s vaccination programmes. IFFIm disbursed a total of US$ 600 million to Gavi for the 2016-2020 strategic period.
IFFIm's contributions have made it possible for Gavi to immunise more children, faster. Adding additional funding to Gavi has saved an estimated 2.9 million children of the 14 million saved overall (as of December 2019). Every $US 1 million investment can save more than 1000 lives.
IFFIm’s value to Gavi
IFFIm delivers value to Gavi by:
- increasing the funding immediately available to Gavi for life-saving vaccines
- accelerating delivery of vaccines and making funding more predictable
- giving Gavi the flexibility to use funds when and where they are needed most
- helping Gavi drive down vaccine prices and secure supply by assuring longterm funding
- empowering donors with a way to spread their contributions over future years while also having an immediate impact
Impact Highlights
Reducing vaccine costs: Pentavalent
IFFIm’s frontloaded funding model helps reduce vaccine costs and shape the market. IFFIm’s support for the pentavalent vaccine provides an example of this mechanism at work. Pentavalent is a vaccine that protects from five diseases (Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib). IFFIm funded more than 90% of the initial vaccine cost for Gavi’s pentavalent programme. This investment encouraged manufactures to increase production and decrease the price. Gavi is now able to procure pentavalent vaccines for $0.68 per dose, a price reduction of more than 75% since 2006.
Eradicating polio
IFFIm has played a critical role in the fight to end polio by providing funding that has helped slash incidence of the disease. When the Global Polio Eradication Initiative (GPEI) faced a crisis in 2006, it turned to IFFIm as the only way to finance stockpiling the polio vaccine so suppliers have it available for outbreaks. IFFIm invested US$191.28 million to help develop and license oral polio vaccine (OPV) products that could be field tested for safety and purchased in bulk. IFFIm’s support contributed to a striking 95% decline in polio cases in Nigeria and India, and an 85 % decline in type 3 polio cases globally.
Success Stories
IFFIm has raised US$ 6.9 billion in the global capital markets to fund Gavi programmes. Learn how IFFIm funds have created a financial lifeline stretching from savvy and socially responsible investors to the world’s poorest communities.
Support for vaccines in Nigeria
IFFIm and Gavi are continuing the fight against vaccine-preventable diseases in Nigeria, where polio is still endemic.
New and underused vaccines
IFFIm supports low-income countries applying for Gavi's new and underused vaccine support.
Immunisation rebounds
Routine immunisation programmes supported by Gavi, with IFFIm funding, have an impact that’s anything but ordinary.
Maternal and neonatal tetanus
Tens of millions of mothers have been been vaccinated with tetanus toxoid thanks to IFFIm support for the MNT Elimination initiative.
Saving Lives: Measles Initiative
IFFIm's investment in the Measles Initiative has played a key part in achieving the goal of reducing measles deaths by 90%.
Health system strengthening
As of December 2017, IFFIm has disbursed US$ 277 million for Gavi's health system strengthening (HSS) support.
IFFIm disbursements support the pentavalent vaccine
IFFIm has provided Gavi with more than US$ 1 billion toward the purchase of pentavalent vaccine.
IFFIm aids the MenAfriVac campaign
Gavi's participation in the campaign against meningitis in Africa has received more than US$ 60 million from IFFIm
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.